Melatonin Attenuates Bax/Bcl‐2 Pathway–Associated Apoptosis After Traumatic Brain Injury Through Enhanced Mitophagy
Acta Neurologica Scandinavica · 2026-01 · 2026 (1)
DOI: 10.1155/ane/7411492 ↗Abstract
Background Traumatic brain injury (TBI) results in permanent neurological deficits, with apoptosis critically affecting outcomes. The Bax/Bcl‐2 pathway–associated mitochondrial apoptosis is a key intrinsic death cascade. Mitophagy is implicated in TBI pathology; however, whether melatonin can regulate Bax/Bcl‐2 pathway–associated apoptosis through mitophagy remains unclear. Methods In vitro and in vivo TBI models were established using HT22 cells subjected to oxygen‐glucose deprivation/reoxygenation and the Feeney weight‐drop mouse model, respectively. Mitophagy was evaluated by measuring changes in LC3B, p62, COX IV, and TOM20 levels via western blotting in both models. In addition, mitochondrial ultrastructure was examined by transmission electron microscopy in vitro, and LC3B/TOM20 and TOM20/LAMP2 colocalization was evaluated by immunofluorescence in vivo. Moreover, Bax and Bcl‐2 expression was detected by western blotting. Apoptosis was evaluated by flow cytometry in vitro and TUNEL staining in vivo. Results TBI enhanced mitophagy, increased the Bax/Bcl‐2 ratio, and augmented apoptosis. Pharmacological inhibition of mitophagy with Cyclosporine A (CsA) further upregulated Bax, downregulated Bcl‐2, and exacerbated apoptotic cell death. Melatonin treatment significantly enhanced mitophagy in both models, leading to a reduced Bax/Bcl‐2 ratio and attenuated apoptosis. Notably, the antiapoptotic effects of melatonin were attenuated by coadministration of CsA, suggesting that its protective action is at least partially mediated by enhanced mitophagy. Conclusion Melatonin attenuates TBI‐induced apoptosis at least in part through enhanced mitophagy, which in turn suppresses the Bax/Bcl‐2 pathway–associated mitochondrial apoptosis. These findings suggest that the mitophagy‐Bax/Bcl‐2 axis may represent a promising therapeutic target, and melatonin warrants further investigation as a potential candidate for TBI treatment.
EUVIMED